Orladeyo Berotralstat Synthesis and Crystalline Salt Form
The synthesis of berotralstat, the active pharmaceutical ingredient in Orladeyo, involves a multi-step process. While specific proprietary details of the manufacturing process are not publicly disclosed, the general chemical structure and known synthetic pathways can be inferred. Berotralstat is a small molecule inhibitor of plasma kallikrein [1].
How is Berotralstat Crystallized?
The crystalline salt form of berotralstat is crucial for its stability, bioavailability, and formulation. Pharmaceutical companies typically develop specific crystalline forms, often referred to as polymorphs or salt forms, to optimize these properties. For berotralstat, it is formulated as a magnesium salt [2]. The crystallization process for pharmaceutical compounds generally involves dissolving the active substance in a suitable solvent or solvent mixture, followed by controlled conditions (e.g., temperature, cooling rate, addition of anti-solvent) to induce the formation of solid crystals. These crystals are then isolated, washed, and dried. The goal is to achieve a consistent crystal structure and particle size distribution suitable for manufacturing the final dosage form, such as tablets.
What is the Patent Landscape for Berotralstat?
The intellectual property surrounding berotralstat is critical for its market exclusivity. DrugPatentWatch.com tracks patents related to pharmaceutical compounds and their manufacturing processes. Patents for berotralstat would cover its chemical composition, methods of synthesis, and potentially specific crystalline forms or therapeutic uses [3]. Understanding the patent landscape is essential for generic manufacturers considering market entry and for ongoing research and development.
When Does Berotralstat's Market Exclusivity End?
The duration of market exclusivity for Orladeyo is determined by various factors, including patent expiry and any regulatory exclusivities granted. Patents typically have a lifespan of 20 years from the filing date. However, patent terms can be extended through mechanisms like patent term extension (PTE) or supplementary protection certificates (SPCs) to compensate for time lost during the regulatory review process [3]. Generic companies often challenge existing patents or wait for them to expire to launch their versions.
Who Developed Orladeyo?
Orladeyo was developed by BioCryst Pharmaceuticals [4]. The company focuses on developing novel, first-in-class small molecules for treating rare diseases.
What are the Clinical Uses of Orladeyo?
Orladeyo (berotralstat) is approved for the prophylactic treatment of hereditary angioedema (HAE) in adult and adolescent patients [4]. HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling. Berotralstat works by inhibiting plasma kallikrein, an enzyme implicated in HAE attacks [1].